Among all groups, DCE at 200 mg/kg consistently yielded the most favorable modulation of these lipid-regulatory proteins, supporting its therapeutic potential in managing MASLD-associated dyslipidemia. This evidence concerns the gene PROS1 and metabolic dysfunction-associated steatotic liver disease.